Are Analysts Bearish Cesca Therapeutics Inc. (NASDAQ:KOOL) After Last Week?

January 13, 2018 - By Adrian Mccoy

 Are Analysts Bearish Cesca Therapeutics Inc. (NASDAQ:KOOL) After Last Week?

Cesca Therapeutics Inc. (NASDAQ:KOOL) Ratings Coverage

Among 2 analysts covering Cesca Therapeutics (NASDAQ:KOOL), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Cesca Therapeutics had 4 analyst reports since August 25, 2015 according to SRatingsIntel. Maxim Group maintained the shares of KOOL in report on Tuesday, November 17 with “Buy” rating. On Tuesday, August 25 the stock rating was upgraded by Zacks to “Sell”. Maxim Group downgraded the stock to “Hold” rating in Tuesday, December 22 report. As per Monday, September 21, the company rating was upgraded by H.C. Wainwright. Below is a list of Cesca Therapeutics Inc. (NASDAQ:KOOL) latest ratings and price target changes.

The stock decreased 1.89% or $0.0605 during the last trading session, reaching $3.1395. About 99,309 shares traded. Cesca Therapeutics Inc. (NASDAQ:KOOL) has declined 16.34% since January 13, 2017 and is downtrending. It has underperformed by 33.04% the S&P500.

Cesca Therapeutics Inc. focuses on the research, development, and commercialization of autologous cell therapeutics for use in regenerative medicine in the United States and internationally. The company has market cap of $34.11 million. The firm develops and makes automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. It currently has negative earnings. The Company’s products include SurgWerks system, a proprietary system comprised of the SurgWerks processing platform, including devices and analytics, and indication-specific SurgWerks procedure kits for use in regenerative stem cell therapy at the point of care for vascular and orthopedic diseases; CellWerks system, a proprietary cell processing system with associated analytics for intra-laboratory preparation of adult stem cells from bone marrow or blood; and AutoXpress system, a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood.

More notable recent Cesca Therapeutics Inc. (NASDAQ:KOOL) news were published by: Seekingalpha.com which released: “Cesca Therapeutics’ (KOOL) Management on Q4 2017 Results – Earnings Call …” on September 20, 2017, also Globenewswire.com with their article: “Cesca Therapeutics Announces Closing of $5 Million Revolving Line of Credit” published on March 13, 2017, Reuters.com published: “BRIEF-Cesca Therapeutics Announces Proposed Public Offering Of Common Stock” on November 28, 2017. More interesting news about Cesca Therapeutics Inc. (NASDAQ:KOOL) were released by: Bizjournals.com and their article: “Cesca Therapeutics aims to raise nearly $3 million with share offering” published on November 29, 2017 as well as Seekingalpha.com‘s news article titled: “Cesca Therapeutics’ (KOOL) CEO Chris Xu on Q1 2018 Results – Earnings Call …” with publication date: November 15, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.